Few recent studies have proposed HE4, a candidate molecular marker for ovarian cancer, as a promising serum marker for endometrial malignancies (Moore et al, 2008; Huhtinen et al, 2009; Montagnana et al, 2009). This evidence concerns the gene WFDC2 and ovarian carcinoma.